Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Janux Therapeutics, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/14/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results|
Docs:
|
"Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights - Presented positive interim Phase 1 clinical trial data for PSMA-TRACTr JANX007 in prostate cancer - Management team bolstered with key appointment - $303.3 million in cash, cash equivalents, and short-term investments at end of second quarter 2023 - In July, further strengthened balance sheet with approximately $60 million offering SAN DIEGO, August 8, 2023 – Janux Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager and Tumor Activated Immunomodulator platforms, today reported financial results for the second quarter ended June 30, 2023, and provided a business..." |
|
| 07/21/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/18/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 07/18/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Underwriting Agreement, between the Company and BofA Securities, Inc.",
"Form of Pre-Funded Warrant",
"Opinion of Cooley LLP",
"Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants SAN DIEGO, July 17, 2023 - Janux Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager and Tumor Activated Immunomodulator platforms, today announced the pricing of an underwritten offering of 4,153,717 shares of its common stock and pre-funded warrants to purchase 583,483 shares of common stock. The shares of common stock are being sold at a price of $12.46 per share and the pre-funded warrants are being sold at a price of $12.459 per pre-funded warrant, which represents the per share price for the common stock less the $0.001 per share ex..." |
|
| 07/17/2023 |
FWP
| Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses: |
| 07/17/2023 |
8-K
| Quarterly results |
| 07/10/2023 |
SC 13G
| CITADEL ADVISORS LLC reports a 5.1% stake in Janux Therapeutics, Inc. |
| 06/16/2023 |
4
| RA CAPITAL MANAGEMENT, L.P. (10% Owner) has filed a Form 4 on Janux Therapeutics, Inc.|
Txns:
| Granted 12,500 options to buy
@ $13.22, valued at
$165.3k
|
|
| 06/16/2023 |
4
| Lichter Jay (10% Owner) has filed a Form 4 on Janux Therapeutics, Inc.|
Txns:
| Granted 12,500 options to buy
@ $13.22, valued at
$165.3k
|
|
| 06/16/2023 |
4
| McNulty Alana B. (Director) has filed a Form 4 on Janux Therapeutics, Inc.|
Txns:
| Granted 12,500 options to buy
@ $13.22, valued at
$165.3k
|
|
| 06/16/2023 |
4
| Simson Jake (Director) has filed a Form 4 on Janux Therapeutics, Inc.|
Txns:
| Granted 12,500 options to buy
@ $13.22, valued at
$165.3k
|
|
| 06/16/2023 |
4
| Kung Winston (Director) has filed a Form 4 on Janux Therapeutics, Inc.|
Txns:
| Granted 12,500 options to buy
@ $13.22, valued at
$165.3k
|
|
| 06/16/2023 |
4
| Gujrathi Sheila (Director) has filed a Form 4 on Janux Therapeutics, Inc.|
Txns:
| Granted 12,500 options to buy
@ $13.22, valued at
$165.3k
|
|
| 06/16/2023 |
4
| CAPPS VICKIE L (Director) has filed a Form 4 on Janux Therapeutics, Inc.|
Txns:
| Granted 12,500 options to buy
@ $13.22, valued at
$165.3k
|
|
| 06/16/2023 |
4
| Barrett Ronald W (Director) has filed a Form 4 on Janux Therapeutics, Inc.|
Txns:
| Granted 12,500 options to buy
@ $13.22, valued at
$165.3k
|
|
| 05/30/2023 |
SC 13G
| BIOTECHNOLOGY VALUE FUND L P reports a 9.8% stake in Janux Therapeutics, Inc. |
| 05/09/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 05/09/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/31/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/10/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/10/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/10/2023 |
8-K
| Quarterly results |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
SC 13G/A
| FMR LLC reports a 13.5% stake in JANUX THERAPEUTICS INC |
| 01/05/2023 |
4
| Winter Charles M. (Chief Technical Officer) has filed a Form 4 on Janux Therapeutics, Inc.|
Txns:
| Granted 100,000 options to buy
@ $14.02, valued at
$1.4M
|
|
| 01/05/2023 |
4
| Robinson Byron (Chief Strategy Officer) has filed a Form 4 on Janux Therapeutics, Inc.|
Txns:
| Granted 100,000 options to buy
@ $14.02, valued at
$1.4M
|
|
|
|
|